Samita S. Andreansky, Ph.D.
- Research Assistant Professor
Dr. Andreansky studies how tumor microenvironment drives negative immune regulators that impacts tumor specific immunity. The working model is that "oncogene addiction" can drive immunosuppression via up regulation of inflammatory mediators. Her laboratory is developing novel therapies with small molecule drugs and oncolytic viruses. Targeted therapy with small molecule drugs isolated from natural compounds was shown to downregulate the activity of Her-2/neu receptor in Her-2/neu positive cancer cells and tumor reduction in Her-2/neu preclinical models.